AstraZeneca drops lead project but not interest in Palatin obesity alliance
This article was originally published in Scrip
AstraZeneca has ended development of the obesity drug AZD2820 from its collaboration with Palatin Technologies following an earlier reported serious adverse event (SAE) during Phase I testing, but the partners will continue to advance other melanocortin agonists for the treatment of obesity.
You may also be interested in...
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.